MedTrace Logo

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

NCT00894868 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 798

Last updated 2020-12-17

No results posted yet for this study

Summary

This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III). Effect on HbA1c and overall safety and tolerability will also be assessed.

Conditions

  • Congestive Heart Failure
  • Type II Diabetes Mellitus

Interventions

DRUG

vildagliptin

DRUG

placebo of vildagliptin

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Czechia
  • Denmark
  • Estonia
  • Germany
  • Greece
  • Guatemala
  • India
  • Italy
  • Latvia
  • Lithuania
  • Poland
  • Romania
  • Russia
  • Singapore
  • Slovakia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00894868 on ClinicalTrials.gov